Pneumococcal conjugate second or third-dose vaccines (PCVc) in Vanuatu
Vanuatu: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 76.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Vanuatu, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Vanuatu is 76.0%, measured in 2025. That is the highest value across all 18 years on record.
Compared with earlier readings it is up 2.7% on the previous year.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Vanuatu peaked at 76.0% in 2025 and was at its lowest, 0.0%, in 2008.
Vanuatu ranks 128th of 194 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Vanuatu, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 0.0% | — |
| 2017 | 0.0% | — |
| 2018 | 0.0% | — |
| 2019 | 0.0% | — |
| 2020 | 0.0% | — |
| 2021 | 39.0% | — |
| 2022 | 42.0% | +7.7% |
| 2023 | 63.0% | +50.0% |
| 2024 | 74.0% | +17.5% |
| 2025 | 76.0% | +2.7% |
Vanuatu compared with similar countries
- Vanuatu's 76.0% is below the median for lower middle income countries, which is 84.0%, 90% of the median. (47 countries reporting)
- Vanuatu's 76.0% is below the median for East Asia & Pacific, which is 81.0%, 94% of the median. (30 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 0.0% | 0.0% | 0.0% | 10 |
| 2020s | 49.0% | 0.0% | 76.0% | 6 |
Countries ranked near Vanuatu
More health data for Vanuatu
- Un projection of annual infant deaths, annual growth rate -2.22 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.8846 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 695.7 deaths per 1,000 people (2090)
- Number of infants who die before age 1 44 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 0.3888 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0639 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.395 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Vanuatu?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Vanuatu was 76.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Vanuatu?
- The highest recorded value was 76.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Vanuatu?
- The lowest recorded value was 0.0% in 2008.
- How does Vanuatu rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Vanuatu ranks 128th out of 194 countries with data for 2025.
- Where does this Vanuatu data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).